Emerging Treatments and Clinical Challenges in Myelodysplastic Syndromes: ASCO 2021 and EHA 2021 Updates | Supplements And Featured Publications

This publication features research that was presented in myelodysplastic syndromes from the 2021 ASCO Annual Meeting and 2021 EHA Congress, including expert perspectives on how the data have clinical implications.

Sponsored by Takeda Oncology/Content Developed Independently by OncLive

Sekeres Previews Potential Combination Strategies in HR-MDS

August 30, 2021

Dr. Sekeres discusses the current unmet needs of patients with higher-risk myelodysplastic syndromes receiving hypomethylating agents, the potential utility of novel combinations in development, and the incorporation of other end points beyond overall survival in clinical trials.

Pevonedistat Shows Promising Partner Potential for HMAs in Higher-Risk MDS

August 03, 2021

Joshua F. Zeidner, MD, discusses the role that HMAs have played in the MDS treatment landscape and shared data reported with promising emerging agents like pevonedistat that can be combined with HMAs to improve outcomes for certain patient subsets.

Imetelstat Elicits Efficacy Across Molecularly Defined Subgroups of Lower-Risk MDS

August 02, 2021

Treatment with imetelstat demonstrated clinical efficacy across molecularly defined subgroups of patients with heavily transfused, lower-risk myelodysplastic syndrome who did not harbor 5q deletions and were relapsed/refractory to erythropoiesis-stimulating agents.

With Novel Combos on the Horizon, End Points Beyond OS May Hold Promise in HR-MDS

July 28, 2021

Novel combinations with agents, such as pevonedistat, eprenetapopt, venetoclax or magrolimab, plus hypomethylating agents like azacitidine are being evaluated to determine whether they can improve upon the lackluster median survival for patients with higher-risk myelodysplastic syndrome.

Pevonedistat Plus HMAs Provides a Promising Strategy in Higher-Risk MDS

July 16, 2021

Daniel Pollyea, MD, MS, discusses the current management of patients with higher-risk myelodysplastic syndrome, the data noted so far with pevonedistat in this paradigm, and other therapies positioned to improve outcomes for this patient population.

Pevonedistat/Azacitidine Could Become New Frontline Standard for Higher-Risk MDS

July 15, 2021

David Sallman, MD, discusses the role of hypomethylating agents in the treatment of patients with higher-risk myelodysplastic syndrome, the promise of pevonedistat in this population, the hunt for biomarkers of response to treatment, and remaining areas of unmet need to address with future efforts.

Pevonedistat-Exposure Outcomes Support Recommended Dose in Higher-Risk MDS/CMML and AML

July 07, 2021

Pevonedistat demonstrated a favorable risk-benefit profile at a dose of 20 mg/m2 in combination with 75 mg/m2 of azacitidine in patients with higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia and acute myeloid leukemia.